Added to YB: 2026-09-09
Pitch date: 2026-09-06
EW [bullish]
Edwards Lifesciences Corporation
-2.64%
current return
Author Info
Welcome to Bio Compounding, where we demystify cutting-edge biotechnology trends and make them accessible to everyone. Sign up for the newsletter.
Company Info
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Market Cap
$51.8B
Pitch Price
$89.07
Price Target
N/A
Dividend
N/A
EV/EBITDA
23.86
P/E
53.64
EV/Sales
7.42
Sector
Health Care Equipment and Supplies
Category
growth
Edwards Lifesciences (EW) — From Valve Pioneer to Structural Heart Powerhouse
EW: Edwards Lifesciences is evolving from a still-growing but maturing TAVR leader into a broader structural-heart franchise, with TMTT positioned as its next multi-billion-dollar business. The case rests first on ageing-driven valve disease, second on treatment gaps of 30-50% in severe symptomatic aortic stenosis and 90-97% in mitral and tricuspid disease, and third on Edwards’ accumulated IP, clinical evidence, physician relationships and manufacturing expertise. Long-term TAVR durability remains the key unresolved issue.
Read full article (10 min)